FULC – fulcrum therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Fulcrum Therapeutics to Present 12-Week Data from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fulcrum Therapeutics (NASDAQ:FULC) is now covered by analysts at JPMorgan Chase & Co.. They set an "overweight" rating and a $20.00 price target on the stock.
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fulcrum Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Form SCHEDULE 13G/A Fulcrum Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
Form 4/A Fulcrum Therapeutics, For: Jan 02 Filed by: Gould Robert J
Form 4 Fulcrum Therapeutics, For: Feb 02 Filed by: Oltmans Curtis Gale
Form 4 Fulcrum Therapeutics, For: Feb 02 Filed by: Musso Alan A
Form 4 Fulcrum Therapeutics, For: Feb 02 Filed by: Gould Robert J
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.